| Synonyms: | |
| Status: | Approved (2018) |
| Entry Type: | Antibody |
| Molecule Category: | UNKNOWN |
| ATC: | L01XC25 |
| UNII: | YI437801BE |
Pharmacology
| Primary Target | |
|---|---|
| CCR4 |
Indications
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Sezary Syndrome | 4 | D012751 | FDA |
| Paraparesis, Tropical Spastic | 3 | D015493 | ClinicalTrials |
| Lymphoma, T-Cell, Cutaneous | 3 | D016410 | ClinicalTrials |
| Lymphoma, T-Cell, Peripheral | 2 | D016411 | ClinicalTrials |
| Leukemia-Lymphoma, Adult T-Cell | 2 | D015459 | ClinicalTrials |
| Carcinoma, Hepatocellular | 1 | D006528 | ClinicalTrials |
| Carcinoma | 1 | D002277 | ClinicalTrials |
| Asthma | 1 | D001249 | ClinicalTrials |
| Carcinoma, Non-Small-Cell Lung | 1 | D002289 | ClinicalTrials |
Cross References
| Resources | Reference |
|---|---|
| CAS NUMBER | 1159266-37-1 |
| ChEMBL | CHEMBL1743041 |
| FDA SRS | YI437801BE |
| Guide to Pharmacology | 6477 |
CONTENTS